Studies reported cereblon (CRBN) as one of the E3 ligase other than VHL E3 ligase, which is commonly expressed in various cancer cell types but less in platelets.[40] This information led researchers to develop CRBN E3 ligase‐based PROTACs to reduce the on‐target platelet toxicity of Bcl‐xL inhibitors. This evidence concerns the gene BCL2L1 and cancer.